Patients with congenital heart disease combined with Eisenmenger’s syndrome have poor surgical outcome and lose the opportunity of surgical treatment. Even if some patients survive the perioperative period, they still have residual pulmonary hypertension after surgery, and some of them continue to have progressive pulmonary hypertension, which seriously threatens their health and life. In determining the indication for surgery, right heart catheterization and acute pulmonary vasodilation test are the international gold standard. However, there is no international consensus on how to accurately distinguish between pulmonary hypertension and Eisenmenger’s syndrome that can be treated surgically. Recent European studies have indicated that if a patient has a small pulmonary artery resistance index <6 Wood unit/m2 during right heart catheterization and a pulmonary circulation resistance to body circulation resistance ratio <0.3, such a patient is feasible for surgical treatment. Surgery is not recommended for patients with a pulmonary small artery resistance index >10 Wood unit/m2. In patients with a pulmonary artery resistance index of 6-9 Wood units/m2 and a pulmonary resistance-to-circulatory resistance ratio of 0.3-0.5, an acute pulmonary vasodilation test is recommended to determine whether surgery is indicated. After the use of pulmonary vasodilators, if the patient’s pulmonary small artery resistance index or pulmonary circulatory resistance to body circulatory resistance ratio decreases by more than 20% from the basal state, pulmonary small artery resistance index <6 Wood unit/m2, and pulmonary circulatory resistance to body circulatory resistance ratio <0.3, then surgical treatment is feasible. In particular, it should be emphasized that in patients who do not have or have lost the indication for surgery, forced surgical treatment will only aggravate the progression of pulmonary arterial hypertension in the patient, and right heart function and total heart failure will occur early after surgery, shortening the patient's life expectancy. Therefore, for patients who have developed Eisenmenger syndrome and lost the opportunity for surgery, the emphasis should be on pharmacological treatment of pulmonary hypertension to achieve the goal of delaying the progression of pulmonary hypertension, improving the patient's clinical symptoms and quality of life, and extending the patient's life expectancy. In our clinical work, we can also intervene by means of internal interventional trial blocking, using a blocker suitable for the size of the patient's defect. If the patient's pulmonary artery pressure drops and aortic blood pressure rises after trial blocking, it means that the trial blocking result is satisfactory, and for such patients, the patient's congenital heart disease and pulmonary hypertension can be cured by minimally invasive methods. In contrast, pharmacological treatment is recommended, with regular follow-up and observation. Due to the scarcity of donors for combined heart-lung transplantation, this treatment can only be applied to a small number of patients. In addition, the perioperative mortality rate of combined heart-lung transplantation is relatively high. According to relevant studies, the 1-year survival rate after combined heart-lung transplantation is about 70%, the 5-year survival rate is 51%, and the 10-year survival rate is 28%. Therefore, only those patients for whom treatment with prostaglandins and their analogues as well as endothelin receptor antagonists is not effective have indications for combined cardiopulmonary transplantation. Due to the advent of targeted therapeutic agents for pulmonary hypertension in recent years, many patients with severe pulmonary hypertension and Eisenmenger syndrome have benefited from treatment that can significantly improve clinical symptoms, quality of life, and life expectancy. In the future, with the further development of medical science, more new drugs for the treatment of pulmonary hypertension will emerge and more patients will benefit from them. Patients who have other related questions can contact me via telephone consultation.